Product image of Ipraxa Steri-Neb (Ipratropium Bromide Monohydrate) supplied by GNH India

Ipraxa Steri-Neb

Active Ingredient:
Ipratropium Bromide Monohydrate
Origin:
EU

Ipraxa Steri-Neb (Ipratropium Bromide Monohydrate)

Ipratropium bromide, the active ingredient in Ipraxa Steri-Neb, is an anticholinergic (muscarinic antagonist) presented as a nebulized solution for inhalation use. It is employed to relieve bronchoconstriction and reduce mucus secretion in patients with chronic obstructive pulmonary disease, asthma and other bronchospastic conditions.

GNH India supplies Ipraxa Steri-Neb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution in multiple regions.

Manufacturer / TM Owner

Teva Nederland B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ipratropium bromide is used as a bronchodilator to manage airway obstruction in several respiratory conditions.

  • Chronic obstructive pulmonary disease (COPD): improves airflow and reduces exacerbations.
  • Asthma (adjunct therapy): enhances bronchodilation when combined with other agents.
  • Bronchospasm: provides rapid relief of acute bronchoconstriction.

How It Works

  • Ipratropium bromide acts as a competitive antagonist at muscarinic acetylcholine receptors M1 and M3 located on airway smooth muscle and submucosal glands. By blocking acetylcholine binding, it prevents calcium‑mediated contraction, leading to relaxation of bronchial smooth muscle and decreased mucus secretion, thereby widening the airways and improving ventilation. The effect is localized to the respiratory tract because the compound has limited systemic absorption, which minimizes systemic anticholinergic effects.

Side Effects

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and related to the inhalation route.

Common Side Effects

  • Dry mouth: sensation of reduced salivation.
  • Cough: irritation of the airway during inhalation.
  • Throat irritation: mild soreness or discomfort.
  • Nasal congestion: blockage or stuffiness.
  • Headache: mild to moderate pain.

Serious or Rare Side Effects

  • Paradoxical bronchospasm: worsening airway narrowing.
  • Allergic reaction: rash, itching, swelling, or anaphylaxis.
  • Urinary retention: difficulty urinating, especially in predisposed patients.
  • Glaucoma exacerbation: increased intra‑ocular pressure.

Precautions & Warnings

Before prescribing Ipraxa Steri‑Neb, consider the following precautions to ensure safe and effective use.

  • Assess respiratory status: confirm diagnosis of COPD, asthma or bronchospasm.
  • Review anticholinergic sensitivity: avoid in patients with known hypersensitivity to ipratropium or similar agents.
  • Monitor for urinary retention: especially in elderly males with prostate enlargement.
  • Caution in glaucoma: use with care in patients with narrow‑angle glaucoma.
  • Avoid concurrent use with long‑acting anticholinergics without medical supervision.
  • Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Ipratropium bromide can interact with other medications; awareness of these interactions helps prevent reduced efficacy or increased adverse effects.

Major Interactions (Avoid)

  • Concurrent long‑acting anticholinergics: may increase anticholinergic burden.
  • Beta‑agonists in high doses: risk of additive cardiovascular effects.

Moderate Interactions (Monitor Closely)

  • Antihistamines: may enhance anticholinergic side effects such as dry mouth.
  • MAO inhibitors: potential for exaggerated bronchodilator response.
  • Ophthalmic anticholinergics: increased risk of intra‑ocular pressure elevation.

Frequently Asked Questions

Ipraxa Steri-Neb contains ipratropium bromide and is prescribed as an inhaled bronchodilator to relieve airway narrowing in chronic obstructive pulmonary disease, to augment asthma therapy, and to treat acute bronchospasm episodes.

Ipratropium bromide blocks muscarinic M1 and M3 receptors in the airways, preventing acetylcholine‑induced smooth‑muscle contraction and mucus secretion. This results in bronchodilation and improved airflow without significant systemic absorption.

The appropriate dose and frequency of Ipraxa Steri-Neb are determined by the prescribing healthcare professional based on the patient’s condition, severity, and response to therapy. Specific dosing instructions should be obtained from the prescriber.

Safety data for ipratropium bromide in pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against possible risks and discuss any concerns with the patient before prescribing.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with short‑acting β2‑agonists, ipratropium provides anticholinergic bronchodilation without stimulating β‑receptors, making it useful as an adjunct or alternative in patients who experience tachycardia or tremor. It is generally less potent than long‑acting anticholinergics but offers a favorable safety profile for short‑term use.

Store the product below 25 °C in its original container, protecting it from moisture, direct sunlight and extreme temperature fluctuations. Keep the vial tightly sealed when not in use and follow any additional handling instructions provided with the shipment.

Ipraxa Steri-Neb is supplied as a nebulized solution for inhalation. The prescribed dose is placed in a compatible nebulizer device, and the patient inhales the aerosolized medication as directed by the healthcare professional.

Serious adverse events include paradoxical bronchospasm, severe allergic reactions such as anaphylaxis, urinary retention in susceptible individuals, and worsening of narrow‑angle glaucoma. Any sudden worsening of breathing or signs of an allergic response should prompt immediate medical attention.

Patients with a known hypersensitivity to ipratropium bromide or any component of the formulation should avoid its use. Caution is also advised for individuals with uncontrolled narrow‑angle glaucoma, urinary retention, or those taking other anticholinergic agents without medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.